Zevra Therapeutics Confirms Nasdaq Listing for ZVRA Common Stock

TL;DR

**ZVRA confirms Nasdaq listing, business as usual.**

AI Summary

Zevra Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose that its Common Stock is registered on The Nasdaq Stock Market under the trading symbol ZVRA. This filing, categorized under Regulation FD Disclosure and Other Events, confirms the company's current listing status and provides updated corporate contact information. For investors, this matters as it reaffirms Zevra's continued compliance with exchange listing requirements, which is crucial for liquidity and investor confidence.

Why It Matters

This filing confirms Zevra Therapeutics' continued listing on Nasdaq, ensuring its stock remains easily tradable for investors.

Risk Assessment

Risk Level: low — This filing is routine and confirms existing information, posing no new risks to investors.

Analyst Insight

A smart investor would note this routine filing confirms Zevra's continued listing on Nasdaq, which is a baseline expectation for publicly traded companies. No immediate action is warranted based solely on this administrative update.

Key Players & Entities

• Zevra Therapeutics, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market (company) — the exchange where Zevra's common stock is registered
• ZVRA (company) — the trading symbol for Zevra Therapeutics' Common Stock
• January 8, 2024 (date) — the date of the earliest event reported in the 8-K
• 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747 (company) — Zevra Therapeutics' business and mail address
• (321) 939-3416 (dollar_amount) — Zevra Therapeutics' business phone number

FAQ

Filing Documents

• zvra20240107_8k.htm (8-K) — 35KB
• ex_612864.htm (EX-99.1) — 16KB
• ex_612869.htm (EX-99.2) — 17KB
• pic01.jpg (GRAPHIC) — 100KB
• pic02.jpg (GRAPHIC) — 212KB
• pic03.jpg (GRAPHIC) — 91KB
• pic04.jpg (GRAPHIC) — 115KB
• pic05.jpg (GRAPHIC) — 135KB
• pic06.jpg (GRAPHIC) — 118KB
• pic07.jpg (GRAPHIC) — 133KB
• pic08.jpg (GRAPHIC) — 108KB
• pic09.jpg (GRAPHIC) — 148KB
• pic10.jpg (GRAPHIC) — 123KB
• pic11.jpg (GRAPHIC) — 99KB
• pic13.jpg (GRAPHIC) — 43KB
• pic14.jpg (GRAPHIC) — 136KB
• pic15.jpg (GRAPHIC) — 86KB
• pic17.jpg (GRAPHIC) — 145KB
• pic19.jpg (GRAPHIC) — 113KB
• pic21.jpg (GRAPHIC) — 91KB
• pic22.jpg (GRAPHIC) — 116KB
• pic23.jpg (GRAPHIC) — 102KB
• pic24.jpg (GRAPHIC) — 131KB
• picture3.jpg (GRAPHIC) — 6KB
• side16.jpg (GRAPHIC) — 66KB
• slide12.jpg (GRAPHIC) — 73KB
• slide18.jpg (GRAPHIC) — 54KB
• slide20.jpg (GRAPHIC) — 60KB
• 0001437749-24-000822.txt ( ) — 3788KB
• zvra-20240108.xsd (EX-101.SCH) — 3KB
• zvra-20240108_def.xml (EX-101.DEF) — 12KB
• zvra-20240108_lab.xml (EX-101.LAB) — 15KB
• zvra-20240108_pre.xml (EX-101.PRE) — 12KB
• zvra20240107_8k_htm.xml (XML) — 3KB

01           Regulation FD Disclosure

Item 7.01           Regulation FD Disclosure.   On January 8, 2024, Zevra Therapeutics, Inc., or the Company, issued a press release announcing that the U.S. Food and Drug Administration, or the FDA, has acknowledged receipt of the Company's resubmission of the New Drug Application, or NDA, for arimoclomol as an orally-delivered, first-in-class treatment for Niemann-Pick disease type C. In addition, the Company updated its corporate presentation.   A copy of the press release and presentation are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K. The information contained in this Item 7.01, the press release furnished as Exhibit 99.1 and the presentation furnished as Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.  

01.           Other Events

Item 8.01.           Other Events .   On January 8, 2024, under the Prescription Drug User Fee Act ("PDUFA"), the FDA has deemed the arimoclomol NDA resubmission to be a Class II complete response which has a six-month review period from the date of resubmission. As a result, the FDA has assigned a PDUFA action date of June 21, 2024, and currently intends to present the resubmission for discussion in an advisory committee.   

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.   The following exhibits relating to Item 7.01 shall be deemed to be furnished, and not filed:   (d)                                          Exhibits   Exhibit No.   Description 99.1   Press Release dated January 8, 2024. 99.2   Corporate Presentation dated January 2024. 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)        

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       Zevra Therapeutics, Inc .           Date: January 8, 2024     By: /s/ R. LaDuane Clifton       R. LaDuane Clifton, CPA       Chief Financial Officer, Secretary and Treasurer    

View Full Filing

View this 8-K filing on SEC EDGAR